DAYTON, Ohio--(BUSINESS WIRE)--Riverain Technologies, an industry leader and innovator in proprietary image analysis and machine learning technologies, announced today that the United States Patent and Trademark Office (USPTO) has awarded the company a broad patent for its technology that forms a vessel suppressed, chest CT series using deep learning and synthetic data modeling. The patent holds enormous promise for improving the detection and diagnosis of lung cancer at an earlier stage while making clinicians more efficient, a first for computer aided detection.
Riverain has been issued U.S. Patent 9,990,743 for its methodology to selectively remove anatomical structures from CT scans to optimize reading accuracy and efficiency for lung cancer detection. The technology is used in the company’s premier software, ClearRead CT™. ClearRead CT is proven to lead to more accurate and efficient detection of lung nodules, the early indicator of lung cancer. A range of possible applications exists within other imaging modalities including MRI, positron emission tomography (PET), full field digital mammography and tomosynthesis, where normal structures interfere with the detection and diagnosis of disease.
Riverain Technologies is a clinical AI software innovator that develops solutions to aid clinicians in the early detection of disease. For more information visit: http://www.riveraintech.com.